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C. Michel Harper, Akira Tsujino, and Margherita Milone
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Congenital myasthenic syndromes (CMSs) stem from genetic defects in endplate (EP)-specific presynaptic, synaptic,
and postsynaptic proteins. The postsynaptic CMSs identified to date stem from a deficiency or kinetic abnormality
of the acetylcholine receptor (AChR). All CMSs with a kinetic abnormality of AChR, as well as many CMSs with
a deficiency of AChR, have been traced to mutations in AChR-subunit genes. However, in a subset of patients with
EP AChR deficiency, the genetic defect has remained elusive. Rapsyn, a 43-kDa postsynaptic protein, plays an
essential role in the clustering of AChR at the EP. Seven tetratricopeptide repeats (TPRs) of rapsyn subserve self-
association, a coiled-coil domain binds to AChR, and a RING-H2 domain associates with b-dystroglycan and links
rapsyn to the subsynaptic cytoskeleton. Rapsyn self-association precedes recruitment of AChR to rapsyn clusters.
In four patients with EP AChR deficiency but with no mutations in AChR subunits, we identify three recessive
rapsyn mutations: one patient carries L14P in TPR1 and N88K in TPR3; two are homozygous for N88K; and one
carries N88K and 553ins5, which frameshifts in TPR5. EP studies in each case show decreased staining for rapsyn
and AChR, as well as impaired postsynaptic morphological development. Expression studies in HEK cells indicate
that none of the mutations hinders rapsyn self-association but that all three diminish coclustering of AChR with
rapsyn.
Introduction
Rapsyn, under the influence of neural agrin, plays a crit-
ical role in concentrating the acetylcholine receptor
(AChR) in the postsynaptic membrane of the motor end-
plate (EP) (Froehner et al. 1990). Rapsyn knockout mice
cluster AChR poorly and fail to accumulate AChR at
the EP (Gautam et al. 1995). Thus, rapsyn is an effector
of agrin-induced clustering of AChR.
Rapsyn binds to the long cytoplasmic loop of each
AChR subunit (Maimone and Merlie 1993, 1999) and
links the receptor to the subsynaptic cytoskeleton via
dystroglycan (Cartaud et al. 1998) and an actin-binding
synaptic nebulin-related anchoring protein (S-NRAP)
(Tseng et al. 2001). The primary structure of rapsyn
predicts distinct structural domains: a myristoylation
signal at the N-terminus, required for membrane as-
sociation (Ramarao and Cohen 1998); seven tetratri-
copeptide repeats (TPRs; codons 6–279) that subserve
rapsyn self-association (Ramarao and Cohen 1998; Ra-
marao et al. 2001); a coiled-coil domain (codons
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298–331) whose hydrophobic surface can bind to de-
terminants within the long cytoplasmic loop of each
AChR subunit (Bartoli and Cohen 2001; Ramarao et
al. 2001); a cysteine-rich RING-H2 domain (codons
363–402) that binds to the cytoplasmic domain of b-
dystroglycan (Bartoli et al. 2001) and to S-NRAP (Tseng
et al. 2001); and a serine phosphorylation site at codon
406.
Self-association of rapsyn is critical for linking AChR
to the cytoskeleton. Rapsyn expressed in human em-
bryonic kidney (HEK) cells or other nonmuscle cells
self-associates into clusters on the cell surface. When
AChR, b-dystroglycan, and S-NRAP are expressed in-
dividually in HEK cells, none aggregates into clusters,
but when AChR (Froehner et al. 1990; Phillips et al.
1991; Ramarao et al. 2001), dystroglycan (Apel et al.
1995; Bartoli et al. 2001), or S-NRAP (Tseng et al.
2001) is coexpressed with rapsyn, each molecule is re-
cruited to existing rapsyn clusters.
Congenital myasthenic syndromes (CMSs) result
from genetic defects in EP-specific presynaptic, synaptic,
or postsynaptic proteins. We and others have identified
genetic defects in presynaptic, synaptic, and postsynap-
tic CMS (Engel et al. 1999). Mutations in the choline
acetyltransferase gene (CHAT [MIM 118490]) result in
decreased vesicular filling with acetylcholine (ACh) and
in a presynaptic CMS (Ohno et al. 2001). Mutations
in the gene encoding the collagenic tail subunit (COLQ
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Figure 1 Pt 2 (left) and Pt 3 (right). In Pt 2, note the bilateral
eyelid ptosis, facial diplegia, and open mouth. Pt 3 shows only mild
eyelid ptosis.
[MIM 603033]) of acetylcholinesterase (AChE) cause a
synaptic form of CMS (Donger et al. 1998; Ohno et al.
1998). Mutations in AChR-subunit genes that alter the
kinetic properties (Ohno et al. 1995; Sine et al. 1995),
the level of expression (Engel et al. 1996), or both
(Ohno et al. 1997) of the receptor result in postsynaptic
CMS. EP AChR deficiency is caused mostly by muta-
tions in the AChR e-subunit gene (CHRNE [MIM
100725]), probably because the fetal AChR g subunit
can partially substitute for the defective adult e subunit
and, thus, can rescue the phenotype (Engel et al. 1996;
Ohno et al. 1997; Milone et al. 1998).
In the course of investigating CMS, we identified 37
patients with deficiency but no kinetic abnormality of
AChR. A rigorous search for mutations in the AChR
a-, b-, d-, and e-subunit genes revealed pathogenic mu-
tations in 27 of these patients. To identify the cause of
AChR deficiency in the other 10 patients, we sequenced
the rapsyn gene (RAPSN [MIM 601592]) and identified
a subset of 4 patients, each carrying two mutant alleles
arising from three mutations. Expression studies of
wild-type or mutant rapsyns cotransfected togetherwith
wild-type AChR subunits in HEK 293 cells reveal that
none of the mutations hinders rapsyn self-association
but that each mutation hinders recruitment of AChR to
rapsyn clusters.
Patients and Methods
Patients
Patient (Pt) 1, a girl of age 2.5 years, and Pt 2, a boy
of age 2 years (fig. 1, left), had weak fetal movements
in utero. In the neonatal period they were hypotonic,
with poor suck and cry and with ptosis of the eyelids.
Pt 1 also required ventilatory assistance for 1 d and tube
feeding for the first 5 mo of life. They walked at age 15
and 18 mo, respectively, but fell frequently. On exami-
nation, they are diffusely weak, have eyelid ptosis, fa-
tigue easily, show a positive Gowers’ sign, and have a
high-arched palate. Pt 3 is a woman of age 27 years. As
an infant, she had a soft cry and fluctuating eyelid ptosis.
She walked at age 18 mo but could never walk fast or
run. On several occasions, respiratory infections or other
intercurrent illnesses precipitated generalized weakness.
On examination, the positive findings are limited to eye-
lid ptosis and the inability to rise from squatting (fig. 1,
right). Pt 4 is a girl of age 11 years. Although her mother
was unaware of decreased fetal movements in utero, she
was born with multiple joint contractures. As a neonate,
she had a weak suck and cry and gained weight poorly.
At age 6 mo and several times in subsequent years,minor
respiratory infections precipitated increased weakness
and respiratory distress requiring assisted ventilation.
On examination, she has mild eyelid ptosis and mild
weakness of the cervical, torso, and limb muscles, and
she fatigues easily on exertion. Pt 1 has a similarly af-
fected brother. Pts 2, 3, and 4 have no similarly affected
family members.
Electromyographic studies revealed a decremental re-
sponse of the compound muscle-fiber action potential
on 2-Hz stimulation in Pts 1 and 2. In Pt 3, single-fiber
electromyography was required to uncover a defect in
neuromuscular transmission. In Pt 4, a decremental re-
sponse on 2-Hz stimulation appeared only after subte-
tanic stimulation for 5 min. All four patients have neg-
ative tests for anti-AChR antibodies and respond
favorably, though incompletely, to anticholinesterase
medications. Pt 3 derives additional benefit from the use
of 3,4-diaminopyridine, a medication that increases the
number of ACh quanta released by nerve impulse.
Muscle Specimens
Intercostal muscle specimens were obtained intact,
from origin to insertion, from patients and from control
subjects without muscle disease who were undergoing
thoracic surgery. All human studies were in accord with
the guidelines of the institutional review board of the
Mayo Clinic.
AChR and AChE were colocalized in cryostat sec-
tions with rhodamine-labeled a-bungarotoxin (a-bgt)
and a monoclonal anti-AChE antibody (Fambrough et
al. 1982). Rapsyn and the vesicular ACh transporter
(VAChT) were colocalized with a mouse anti-rapsyn
monoclonal (mAb 1234, 2 mg/ml; a gift from S. Froeh-
ner) and a polyclonal rabbit anti-VAChT (1/500; a gift
from J. D. Erickson) as primary antibodies, and with
fluorescein-isothiocyanate (FITC)–labeled donkey anti-
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mouse IgG (5 mg/ml) and CY3-labeled donkey anti-
rabbit IgG (1 mg/ml) as second antibodies (Jackson
Laboratories).
EPs were localized for electron microscopy (Engel
1994a) and were quantitatively analyzed (Engel 1994b)
by established methods. Peroxidase-labeled a-bgt was
used for the ultrastructural localization of AChR (Engel
et al. 1977). The number of AChRs per EP wasmeasured
with a-bgt labeled with 125I, as described by Engel
(1993).
Electrophysiology of Muscle Specimens
Miniature EP (MEPP), miniature EP current (MEPC),
and EP potential (EPP) recordings, as well as estimates
of the number of transmitter quanta released by nerve
impulse (Engel et al. 1993; Uchitel et al. 1993) and sin-
gle-channel patch-clamp recordings from the EP in the
cell-attached mode (Milone et al. 1997), were performed
as described elsewhere.
Sequencing Procedures
PCR-amplified fragments were purified by the QIA-
quick 8 PCR Purification Kit (Qiagen). Plasmids were
purified by the QIAprep Spin Miniprep Kit (Qiagen).
PCR products and plasmids were sequenced with an
ABI377 DNA sequencer (PE Biosystems), using fluores-
cently labeled dideoxy terminators.
Mutation Analysis
DNA was isolated from muscle and blood, as de-
scribed by Ohno et al. (1995). We sequenced all exons
of the AChR a-, b-, d-, and e-subunit genes, along with
their flanking noncoding regions, as described elsewhere
(Ohno et al. 1995). To sequence RAPSN, we used the
genomic sequence of RAPSN (GenBank accession num-
ber AC074195) and synthesized five pairs of PCR prim-
ers to amplify and directly sequence eight exons and their
flanking noncoding regions. After identifying mutations
inRAPSN,we used allele-specific PCR to screen relatives
of patients for the three observed mutations and to
screen 400 normal alleles for the two missense
mutations.
cDNA Cloning of Human RAPSN
We used nested RT-PCR to amplify the entire coding
region of RAPSN from normal human muscle mRNA.
The nested forward primer introduced the Kozak con-
sensus sequence (5′-CCACC-3′; Kozak 1987) before the
translational start site. The nested forward and reverse
primers also carried the EcoRI- and BamHI-recognition
sites, respectively, at their 5′ ends. Thus, the PCR product
from the 5′ end included an EcoRI site; the Kozak con-
sensus sequence; nucleotides 1–1239 of RAPSN, with
the first nucleotide corresponding to the translational
start site; and a BamHI site. The PCR product was then
ligated into pEGFP-N1, a plasmid harboring the gene
encoding enhanced green fluorescent protein (EGFP;
Clontech), to attach EGFP to the C-terminal end of rap-
syn (Ramarao and Cohen 1998).
The L14P and N88K missense mutations were intro-
duced into pEGFP-RAPSN through use of the Quik-
Change Site Direct Mutagenesis Kit (Stratagene). Be-
cause direct introduction of 553ins5 into pEGFP-
RAPSN abolishes EGFP translation, we eliminated a
premature stop codon generated by 553ins5. We first
PCR-amplified the wild-typeRAPSN in pEGFP, from the
Kozak consensus sequence to nucleotide 604. The for-
ward and reverse primers carried the EcoRI- and
BamHI-recognition sites, respectively, at their 5′ ends.
After the PCR product was ligated into pEGFP-N1,
553ins5 was introduced using the QuikChange Site Di-
rect Mutagenesis Kit. This construct encodes a truncated
RAPSN (codons 1–184), 19 missense codons generated
by 553ins5, and EGFP followed by a stop codon. For
each construct, the presence of the introduced mutation
and absence of unwanted artifacts was confirmed by
sequencing of the entire insert.
Identification of Consensus cDNA Sequence of RAPSN
Compared to our clone, the published cDNA sequence
(GenBank accession number Z33905; Buckel et al.
1996) harbors 13 discordant nucleotides in 12 codons,
as well as 42 discordant nucleotides in its 5′ and 3′ non-
coding regions. The substitutions are synonymous in
eight codons and nonsynonymous in four. When 34 hu-
man alleles were analyzed, we found none that contained
the discordant nucleotides in either their coding or non-
coding regions. Also, the high-throughput genomic se-
quence ofRAPSN, reported by the Human Genome Pro-
ject (GenBank accession number AC074195), carries
none of the discordant nucleotides in Z33905. There-
fore, our clone likely has the human consensus sequence
for RAPSN, and we posted it in the GenBank gene da-
tabase (GenBank accession number AF449218).
Expression Studies in HEK Cells
Wild-type and mutant RAPSN-EGFP constructs were
made, as described above. Human a- and d-subunit
cDNAs were a gift from J. Lindstrom (Schoepfer et al.
1988; Luther et al. 1989). The b- and -subunit cDNAs
were cloned from normal human skeletal muscle (Ohno
et al. 1996). All four cDNAs were subcloned into the
CMV-based expression vector pRBG4 (Ohno et al.
1996).
HEK cells were maintained at 37C inDulbecco’smin-
imal essential medium (DMEM) supplemented with
10% fetal bovine serum. Cells were grown on 22-mm
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Figure 2 Two-color fluorescence localization at EPs of AChE (A
and C) with AChR (B and D) and of VAChT (E and G) with rapsyn
(F and H), in a control subject (A, B, E, and F) and in Pt 1 (C, D, G,
and H). Note the marked attenuation of the signal for AChR (D) and
rapsyn (H) at the patient EP. Bar p 50 mm.
Figure 3 Cholinesterase-reactive EP region in Pt 3 (A) and in a
control subject (B). Note the dispersion of EP regions over an extended
length of the muscle fiber in the patient. C, Typical EP regions in Pt
4. The postsynaptic area of folds and clefts is shallow and displays
few secondary clefts. D and E, Ultrastructural localization of AChR
with peroxidase-labeled a-bgt at an EP from Pt 3 (D) and at a control
EP (E). At the patient EP, the reaction for AChR is attenuated and the
length of the postsynaptic membrane reacting for AChR is reduced.
Bar in A (which also applies to B) p 25 mm; bar in E (which also
applies to C and D) p 1 mm.
cover slips coated with rat tail collagen type I (BD Bi-
osciences), in six-well plates. Cells were transfected 48
h after plating, by the calcium phosphate method. Wild-
type or mutant RAPSN-EGFP constructs (2.5 mg) were
transfected with or without AChR-subunit cDNAs, at a
ratio of 2:1:1:1 for a (2.5 mg), b, d, and , respectively.
Additional cells were transfected with AChR-subunit
cDNAs only. To obtain optimal surface expression of
rapsyn and AChR, the preparations were evaluated 30
h after transfection (Ramarao and Cohen 1998). Surface
expression of AChR was visualized by incubation with
125 nM a-bgt labeled with rhodamine (Molecular
Probes) in DMEM for 1 h at 37C, followed by three
rinses with DMEM and one with PBS over 30min. Next,
the cells were fixed with 2% paraformaldehyde in PBS
for 20 minutes, rinsed with PBS, and then mounted un-
der Vectashield (Vector Laboratories). Each transfection
was repeated three or more times.
The preparations were analyzed with a Zeiss epiflu-
orescence microscope, using a 100# Neofluar objective
(numerical aperture [NA] 1.3), with FITC optics em-
ployed to visualize rapsyn-EGFP and rhodamine optics
employed to visualize AChR. After transfections with
wild-type or mutant rapsyn, each cover slip was syste-
matically traversed until 100 cells expressing rapsyn, dis-
tributed either diffusely or in clusters, were encountered,
and the proportion of cells displaying rapsyn in clusters
was determined. After cotransfection ofwild-type ormu-
tant rapsyn along with AChR, each cover slip was sys-
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Table 1
Morphometric Analysis of EP Regions
PATIENT
OR SAMPLE
MEANSTANDARD ERRORa
Nerve Terminal Area
(mm2)
Postsynaptic Area
(mm2)
No. of Secondary Clefts per
Micrometer of Primary Cleft AChR Index
Pt 1 2.24.21 (n p 39) 2.24.21 (n p 39) .57.078 (n p 39) 1.12.14 (n p 14)
Pt 2 3.04.35 (n p 31) 2.68.20 (n p 31) .48.073 (n p 31) 1.04.080 (n p 37)
Pt 3 3.16.46 (n p 27) 2.80.30 (n p 27) .38.069 (n p 27) 1.27.10 (n p 30)
Pt 4 2.57.38 (n p 39) 1.84.13 (n p 39) .22.043 (n p 39) NDb
Controls 3.88.39 (n p 63) 10.60.79 (n p 54) 1.58.056 (n p 88) 3.01.11 (n p 85)
a n represents the number of EP regions. More than one EP region can occur at one EP.
b ND p not determined.
Table 2
a-bgt Binding Sites per EP and Microelectrode Studies of Neuromuscular Transmission
PATIENT
OR SAMPLE
MEANSTANDARD ERRORa
No. of [125I]a-bgt
Binding Sites per EP
(#106)
EPP Quantal
Contentb
MEPP Amplitudec
(mV)
MEPC Amplituded
(nA)
Burst Open Duratione
(ms)
Pt 1 1.6 192 (n p 19) .13.024 (n p 17) .81.035 (n p 31) 2.46.31 (n p 7)
Pt 2 .59 2510 (n p 14) .12.0090 (n p 14) 1.29.068 (n p 22) 2.50.33 (n p 5)
Pt 3 5.7 607 (n p 23) .47.033 (n p 13) 1.83.15 (n p 10) 3.21.21 (n p 3)
Pt 4 6.1 398 (n p 11) .41.047 (n p 8) 1.32.098 (n p 14) 2.68.19 (n p 5)
Controls 12.82.79; 4.7f 311; 181.5g 1.00.025 (n p 164) 3.95.10 (n p 79) 2.99.26 (n p 7)
a n represents the number of EPs. Temperatures were 29.5C for EPP and MEPP recordings and 22.5C for MEPC studies
and patch-clamp studies.
b Quantal content of EPP at 1-Hz stimulation, corrected for a resting membrane potential of 80 mV, nonlinear summation, and
non-Poisson release.
c Corrected for a resting membrane potential of 80 mV and a mean muscle-fiber diameter of 55 mm.
d Membrane potential p 80 mV.
e ACh p 1 mM for control individuals and 1–5 mM for patients; bandwidth p 12 kHz for control individuals and 10–12 kHz
for patients; membrane potential p 80mV.
f The first value is for 13 adults, and the second value is for one individual of age 3 years.
g The first value is for 190 adult EPs, and the second value is for 18 EPs in one individual of age 3 years.
tematically traversed until 100 cells expressing clustered
rapsyn and diffusely distributed or clustered AChRwere
encountered, and the proportion of cells in which the
receptor coclustered with rapsyn was determined. After
transfection with AChR only, we examined 100 AChR-
expressing cells and determined the number of cells ex-
pressing AChR diffusely or in clusters. Images for pub-
lication were obtained with a Zeiss LSD confocal
microscope (green fluorescence: 488 nm excitation,
505–550 nm emission; red fluorescence: 543 nm exci-
tation, 1560 nm emission), using a 100# Planapochro-
mat objective (NA 1.4).
Results
EP Studies
Histochemical studies of intercostal muscle specimens
revealed a type 1–fiber preponderance in each patient.
On fluorescence microscopy, AChE (fig. 2A and C) and
VAChT (fig. 2E and G) were preserved, but AChR (fig.
2D) and rapsyn (fig. 2H) were markedly attenuated at
all patient EPs. These findings do not establish whether
deficiency of rapsyn or of AChR is the primary abnor-
mality, for rapsyn expression is also reduced when EP
AChR deficiency stems from low-expressor mutations in
AChR-subunit genes (A.G.E., unpublished data).
The configuration of the EPs, evaluated from the cy-
tochemical reaction product for AChE on longitudinally
oriented teased single muscle fibers, was abnormal, with
an increased number of small EP regions (2–7 in Pt 1,
1–3 in Pt 2, and as many as 12 in Pts 3 and 4) distributed
over an increased span of the muscle-fiber surface (fig.
3A and B).
On electron microscopy, the structural integrity of the
nerve terminals and junctional folds was preserved, but
the postsynaptic area of clefts and folds was only
17%–26% of normal, and the frequency of secondary
clefts per unit length of the primary synaptic cleft was
only 14%–36% of normal (table 1; fig. 3C and D),
indicating impaired morphological development of the
postsynaptic region. Ultrastructural localization of
AChR with peroxidase-labeled a-bgt revealed a marked
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Table 3
Identified RAPSN Mutations
Patient and
Nucleotide Change
Amino Acid
Change Domain
1:
41TrC L14P TPR1
264CrA N88K TPR3
2:
264CrA N88Ka TPR3
3:
264CrA N88Ka TPR3
4:
264CrA N88K TPR3
553ins5 Frameshift TPR5
a Homozygous mutation.
Figure 4 A, Alignment of amino acid sequences of Torpedo cal-
ifornica, Xenopus, chicken, mouse, and human rapsyn. Identified mu-
tations and functional domains are indicated. The 553ins5 mutation
predicts 19 missense codons (boldface), followed by a stop codon
(indicated by an asterisk [*]). The far-right column indicates amino
acid numbers. B, Allele-specific PCR of family members. Affected
members (shaded symbols) carry two mutant alleles. Unaffected mem-
bers harbor no (unshaded symbols) or one (half-shaded symbols) mu-
tant allele, indicating that each mutation is heteroallelic and recessive.
Arrows indicate propositi. Unshaded arrowheads indicate normal frag-
ments; shaded arrowheads point to mutant fragments. “F1”–“F4”
indicate families 1–4.
decrease in the density and distribution of AChR on the
postsynaptic membrane (fig. 3D and E). The AChR in-
dex (defined as the length of the postsynaptic membrane
reacting for AChR, normalized for the length of the pri-
mary synaptic cleft) was reduced to 35%–42% of nor-
mal (table 1). The structural abnormalities at the EPs
were similar to those found in patients with low-ex-
pressor mutations in AChR-subunit genes (Engel et al.
1996; Ohno et al. 1997; Quiram et al. 1999).
The numbers of AChRs per EP were 34%, 8%, 44%,
and 48% of the control values (table 2). In Pts 1, 3, and
4, this decrease was less marked than suggested by vi-
sualization of AChR with rhodamine- and peroxidase-
labeled a-bgt. A possible explanation for this discrep-
ancy is that the increase in EP regions—and, hence, in
the postsynaptic surface per EP—is greater in Pts 1, 3,
and 4 than in Pt 2 (Engel 1993). Alternatively, unclus-
tered AChR may go undetected on staining with rho-
damine- or peroxidase-labeled a-bgt but is counted with
125I-a-bgt.
On electrophysiological studies, quantal release by
nerve impulse was higher than normal in Pts 3 and 4,
and in Pts 1 and 2 it was comparable to that in a control
subject of age 3 years. Consistent with EP AChR defi-
ciency, the MEPP amplitudes were reduced to 13%,
12%, 47%, and 33% of normal, and the MEPC am-
plitudes were reduced to 25%, 32%, 46%, and 33% of
normal. Single-channel patch-clamp recordings obtained
from each patient’s EPs showed that the AChR channels
opened to a normal conductance of ∼60 picoSiemens
and that the duration of the predominant component of
channel-opening bursts was not significantly different
from normal (table 2).
To summarize, EP studies demonstrate (1) AChR and
rapsyn deficiency and (2) impaired morphological de-
velopment of the postsynaptic region but (3) no decrease
of ACh release by nerve impulse or kinetic abnormality
of the AChR channel.
Mutation Analysis
Because we detected no mutations on direct sequenc-
ing of AChR a-, b-, d-, and -subunit genes, we next
directly sequenced the eight exons of RAPSN with their
flanking untranslated regions and identified three mu-
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Figure 5 Expression studies in HEK cells. A, Percentage of rap-
syn-positive cells with rapsyn clusters. B, Percentage of AChR-ex-
pressing cells with AChR clusters. The first bar indicates the percentage
of AChR-positive cells with AChR clusters after transfection with
AChR only; the next four bars indicate percentage of rapsyn- and
AChR-positive cells in which AChR coclusters with wild-type or mu-
tant rapsyns. Results are shown as meanSD. Asterisks (*) indicate
.P ! .001
Figure 6 Expression of (A) wild-type, (B) L14P-, (C) N88K-,
and (D) 553ins5-rapsyn-EGFP, in HEK cells. Abundant rapsyn clusters
appear in cells expressing wild-type or mutant rapsyns. Barp 20 mm.
tations in four patients (table 3). Pts 1 and 4 are het-
erozygous for two mutations, whereas Pts 2 and 3 are
homozygous for a single mutation. Analysis of family
members revealed that the two mutations in Pts 1 and
4 are heteroallelic and that all three mutations are re-
cessive (fig. 4B). Neither L14P nor N88K was detected
in 400 normal alleles. Both leucine at codon 14 and
asparagine at codon 88 are conserved in Torpedo cali-
fornica (Frail et al. 1987), Xenopus (Frail et al. 1987),
chicken (Burns et al. 1996), and mouse (Frail et al. 1988;
Froehner 1989) (fig. 4A).
Mutation analysis also revealed four polymorphisms
in the RAPSN coding region: 172C/T, predicting R58C,
and synonymous polymorphisms 456T/C, 855G/A, and
1143T/C; these four polymorphisms had respective al-
lelic frequencies of 19/192, 25/34, 4/34, and 25/34. The
456T/C and 1143T/C polymorphisms are linked in all
individuals.
Expression Studies in HEK Cells
To determine the mechanism by which the observed
rapsyn mutations result in EP AChR deficiency, we en-
gineered wild-type and mutant rapsyn-EGFP with or
without AChR subunits, or AChR subunits alone, into
HEK cells.
After transfection with the wild-type rapsyn-EGFP,
51% of rapsyn-expressing cells displayed !1- to ∼3-mm
rapsyn granules (figs. 5A and 6A). After transfection
with L14P-, N88K-, and 553ins5-rapsyn-EGFP, a similar
proportion of rapsyn-positive cells displayed rapsyn
granules (figs. 5A and 6B–D). Thus, none of the mu-
tations hinders rapsyn self-aggregation in HEK cells.
After transfection of HEK cells with AChR but with-
out rapsyn, only 2% of cells expressing surface AChR
displayed sparse AChR granules. After cotransfection of
AChR with wild-type rapsyn-EGFP, AChR coclustered
with rapsyn in 87% of cells that displayed rapsyn gran-
ules (figs. 5B and 7A–C). After transfection of HEK cells
with AChR plus L14P-, N88K-, and 553ins5-rapsyn-
EGFP, AChR coclustered with rapsyn in only 10%,
30%, and 8%, respectively, of cells with rapsyn granules
(figs. 5B and 7D–F, G–I, and J–L). In those cells in which
AChR did cocluster with mutant rapsyn, only a few of
the rapsyn-positive granules were also AChR-positive
(see fig. 7F, I, and L). Thus, although L14P, N88K, and
553ins5 do not affect self-aggregation of rapsyn-EGFP
in HEK cells, each mutation significantly compromises
recruitment of AChR to rapsyn clusters.
Discussion
We here identify a subset of patients with CMS who
have EP AChR deficiency caused not by mutations in
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Figure 7 Distribution of rapsyn (green signal, A–J), surface
AChR (red signal, B–K), and superimposed images (C–L), in cells
cotransfected with AChR and wild-type rapsyn (A–C), L14P-rapsyn
(D–F), N88K-rapsyn (G–I), and 553ins5-rapsyn (J–L). The imaged
cells were selected to show coclustering of AChRwith rapsyn; however,
whereas AChR coclustered with 87% of cells expressing both AChR
and wild-type rapsyn, AChR coclustered with L14P-, N88K-, and
553ins5-rapsyn in only 102.8%, 303.4%, and 81.7% of cells,
respectively, and, in these cells, only a few rapsyn-positive granules
were also AChR-positive (yellow granules in F, I, and L). Bar p 10
mm.
an AChR-subunit gene but by mutations in rapsyn. It is
important to note, however, that other EP-specific pro-
teins involved in the regulation of AChR expression or
in aggregation at the EP could also cause EP AChR de-
ficiency. These proteins include neural agrin (Gautam et
al. 1996; Burgess et al. 1999); MuSK (Glass et al. 1996);
the predicted proteinMASC, which enables agrin to bind
to MuSK (Glass et al. 1996); the predicted protein
RATL, which functionally couples MuSK to rapsyn
(Apel et al. 1997); Src, Fyn, and Yes kinases signaling
downstream from MuSK (Smith et al. 2001); b-dystro-
glycan (Cartaud et al. 1998); S-NRAP (Tseng et al.
2001); neuregulin and its signaling molecules (Si et al.
1996; Altiok et al. 1997; Sandrock et al. 1997); neu-
rotrophin-4 (Belluardo et al. 2001) and its receptor, TrkB
(Gonzales et al. 1999); as well as a-dystrobrevin (Newey
et al. 2001), utrophin (Grady et al. 1997), and a-syn-
trophin (Adams et al. 2000). No mutations in these mol-
ecules in humans have been detected to date.
Phenotype Effects
In each patient, the safety margin of neuromuscular
transmission is compromised by the EP AChR deficiency,
which is secondary to the rapsyn deficiency. The con-
sequences of EP AChR deficiency are abetted by the
incompletely developed postsynaptic region, which is
nearly devoid of junctional folds. The junctional folds
increase the series resistance of the postsynaptic
membrane (Martin 1998), and their troughs are enriched
in Na channels, factors that augment the synaptic re-
sponse to ACh (Wood and Slater 1997; Ruff 1998). Ab-
sence of junctional folds from the EP is estimated to
result in a two- to fourfold decrease in the safety factor
of neuromuscular transmission (Wood and Slater 1997).
We discerned no clear phenotype-genotype correlation
in our patients. Pts 2 and 3 are homozygous for the same
N88K mutation, but Pt 2 has severe myasthenic symp-
toms at age 2 years, whereas Pt 3 has only mild weakness
at age 27 years. Pt 1, who is heterozygous for N88K
and L14P, is as severely affected as Pt 2, and Pt 4, who
harbors N88K and 553ins5 and was born with arthro-
gryposis, has only mild weakness at age 11 years. The
variable phenotypic expressivity of the mutations may
be caused by single-nucleotide polymorphisms in func-
tionally related genes that govern (1) quantal release by
nerve impulse, which was increased in Pts 3 and 4; (2)
development of multiple small EP regions, which was
most pronounced in Pts 3 and 4; or (3) other factors.
Structural Consequences of the Mutations
The 553ins5 mutation significantly decreases coclus-
tering of rapsyn with AChR in HEK cells. This mutation
causes a frameshift in TPR5 and thus prevents expres-
sion of TPRs 6 and 7 and of the coiled-coil and RING-
H2 domains. Since the coiled-coil domain interacts with
AChR (Ramarao et al. 2001), and since the RING-H2
domains interact with S-NRAP (Tseng et al. 2001) and
b-dystroglycan (Bartoli et al. 2001), 553ins5 is predicted
to abrogate the coclustering of AChR, dystroglycan, and
S-NRAP with rapsyn.
L14P and N88K also decrease coclustering of rapsyn
with AChR in HEK cells, which implies that the effects
of L14P in TPR1 and of N88K in TPR3 propagate
downstream to the coiled-coil domain. Possible expla-
nations could be that L14P and N88K cause abnormal
folding of rapsyn, hindering association with its binding
partners, or that the mutations have an allosteric effect
on the conformation of the coiled-coil and RING-H2
domains. One can also assume that similarmechanism(s)
operate in a recently reported animal model of rapsyn
deficiency caused by a point mutation in a TPR domain
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of the zebrafish, Danio rerio. These fish show reduced
expression of AChR at the EP and have a myasthenic
phenotype (Ono et al. 2001).
Rapsyn and AChR Expression at the EPs
Decreased recruitment of AChR to rapsyn clusters, as
well as decreased rapsyn expression at the EPs, are likely
to account for the EP AChR deficiency. A number of
factors likely contribute to the reduced expression of
rapsyn at the EPs. (1) Low-expressor mutations in
AChR-subunit genes result in decreased rapsyn expres-
sion at the EPs. This implies that rapsyn clusters are
stabilized by association with AChR. Conversely, a de-
creased association of the mutant rapsyns with AChR
could result in EP rapsyn deficiency. (2) Accelerated deg-
radation of abnormally folded nascent mutant peptides
in the endoplasmic reticulum (Mori 2000) could also
contribute to the rapsyn deficiency. (3) The expression
of the 553ins5-rapsyn could also be diminished by non-
sense-mediated mRNA decay (Frischmeyer and Dietz
1999) and by loss of anchorage to the subsynaptic cy-
toskeleton, due to absence of the RING-H2 domain.
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